secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2026-08-13T12:31:59+00:00
Accession:  0001193125-26-347984
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q2 net loss narrows to $30.2M; first patient dosed in lupus nephritis registrational trial
--------------------------------------------------------------------------------

- Net loss $30.2M ($0.25/share) vs $34.1M ($0.29/share) in Q2 2025; revenue $2.1M from Ono collaboration.
- Cash $153.8M at June 30, down $21M in quarter; runway expected into 2028.
- First patient dosed in RECLAIM-LN Phase 2 registrational trial for lupus nephritis with FT819; outpatient same-day discharge.
- FDA cleared IND for FT839 dual CD19/CD38 CAR T; Phase 1/2 basket trial in autoimmune disease planned.
- Preliminary SSc data: all 4 patients achieved rCRISS≥25 and mRSS improvement; no CRS/ICANS/GvHD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312526347984/0001193125-26-347984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312526347984/fate-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-347984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer